



Jubilant Life Sciences Ltd.
1A, Sector 16A
Noida – 201301, India

PRESS RELEASE

**Jubilant repays US\$ 202Mn for outstanding FCCBs
including YTM of US\$60Mn**

Noida, India, May 23, 2011

Jubilant Life Sciences Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced the prompt repayment of US\$ 202 million on account of outstanding FCCBs including YTM of US\$ 60 million. With this repayment, no more FCCBs are outstanding in the books.

The Company has repaid all the outstanding FCCBs on time, as per schedule, in line with the terms and conditions of the FCCB instruments, showing its commitment to meet its obligation on time and demonstrating its financial strength.

Commenting on the development, Chairman & Managing Director, Shyam S. Bhartia and Co-Chairman & Managing Director, Hari S. Bhartia said "It has been our objective to strengthen our balance sheet by using a more optimal mix of capital. After the repayment of our last FCCBs amounting to US\$ 202 million, there are no major debt repayments due for the next 3 years. We have good visibility of growth and have exciting plans to augment capacities, introduce products and enter new markets across our lines of businesses, thereby driving revenue and earnings growth momentum for the Company."



About Jubilant

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider out of India. The Company provides Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities and a team of ~ 5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 60 countries. The Company is well recognized as a 'Partner of Choice' by leading life sciences companies worldwide. For more info: www.jubl.com

For more information please contact:

For Investors

Nidhi Aggarwal
Jubilant Life Sciences Limited
Ph: +91-120 4361002
E-mail: nidhi_aggarwal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 -22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Seema Ahuja
Jubilant Life Sciences Limited
Ph: +91-120 4361062, Cell: +91 9810631779
E-mail: seema_ahuja@jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.